How to Interpret New Data View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2004

AUTHORS

Robert P. Heaney

ABSTRACT

Instead of relying mainly on personal experience with new diagnostic and treatment methods, a wise physician depends on studies reported in the medical literature.Proof of efficacy of new agents is currently provided by double-blind, randomized, placebo-controlled trials (RCTs), generally involving more than one medical center.Relative risk values alone give incomplete information. It is necessary to know also the basal risk of the outcome in question and to assess its importance, both medically and personally.Cost/benefit analyses have become increasingly important in the development of practice guidelines, in the registration of drugs, and in the deployment of screening tests and preventive regimens.The results of treatment trials of bone active agents must be analyzed in a way that is consistent with the underlying biology.A physician tries a new bone active agent in his practice. His patients seem to improve and he is enthusiastic. Another physician, trying the same agent, sees little patient improvement but notes serious side effects and becomes convinced that the drug is more trouble than it is worth. Both are wrong, as the Hippocratic maxim suggests. It is impossible to say in individual cases how much of the difference between the two experiences is due to placebo effects, to variations in the biologic makeup of the patients concerned, or simply to random chance. More... »

PAGES

213-217

Book

TITLE

Osteoporosis in Clinical Practice

ISBN

978-1-85233-757-5
978-0-85729-402-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-0-85729-402-9_28

DOI

http://dx.doi.org/10.1007/978-0-85729-402-9_28

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043009411


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "familyName": "Heaney", 
        "givenName": "Robert P.", 
        "id": "sg:person.0645437522.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645437522.96"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2004", 
    "datePublishedReg": "2004-01-01", 
    "description": "Instead of relying mainly on personal experience with new diagnostic and treatment methods, a wise physician depends on studies reported in the medical literature.Proof of efficacy of new agents is currently provided by double-blind, randomized, placebo-controlled trials (RCTs), generally involving more than one medical center.Relative risk values alone give incomplete information. It is necessary to know also the basal risk of the outcome in question and to assess its importance, both medically and personally.Cost/benefit analyses have become increasingly important in the development of practice guidelines, in the registration of drugs, and in the deployment of screening tests and preventive regimens.The results of treatment trials of bone active agents must be analyzed in a way that is consistent with the underlying biology.A physician tries a new bone active agent in his practice. His patients seem to improve and he is enthusiastic. Another physician, trying the same agent, sees little patient improvement but notes serious side effects and becomes convinced that the drug is more trouble than it is worth. Both are wrong, as the Hippocratic maxim suggests. It is impossible to say in individual cases how much of the difference between the two experiences is due to placebo effects, to variations in the biologic makeup of the patients concerned, or simply to random chance.", 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-0-85729-402-9_28", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-85233-757-5", 
        "978-0-85729-402-9"
      ], 
      "name": "Osteoporosis in Clinical Practice", 
      "type": "Book"
    }, 
    "keywords": [
      "bone active agents", 
      "placebo-controlled trial", 
      "serious side effects", 
      "relative risk values", 
      "proof of efficacy", 
      "basal risk", 
      "registration of drugs", 
      "preventive regimens", 
      "treatment trials", 
      "patient improvement", 
      "practice guidelines", 
      "Medical Center", 
      "new agents", 
      "side effects", 
      "placebo effect", 
      "Hippocratic maxim", 
      "medical literature", 
      "active agents", 
      "same agents", 
      "physicians", 
      "patients", 
      "treatment methods", 
      "individual cases", 
      "trials", 
      "drugs", 
      "wise physician", 
      "agents", 
      "regimens", 
      "efficacy", 
      "more trouble", 
      "outcomes", 
      "risk", 
      "risk values", 
      "personal experience", 
      "guidelines", 
      "effect", 
      "experience", 
      "differences", 
      "cases", 
      "center", 
      "study", 
      "chance", 
      "test", 
      "random chance", 
      "improvement", 
      "benefit analysis", 
      "practice", 
      "literature", 
      "registration", 
      "data", 
      "development", 
      "biology", 
      "cost/benefit analysis", 
      "makeup", 
      "new data", 
      "importance", 
      "analysis", 
      "results", 
      "trouble", 
      "information", 
      "values", 
      "questions", 
      "method", 
      "variation", 
      "proof", 
      "way", 
      "maxim", 
      "incomplete information", 
      "deployment"
    ], 
    "name": "How to Interpret New Data", 
    "pagination": "213-217", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043009411"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-0-85729-402-9_28"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-0-85729-402-9_28", 
      "https://app.dimensions.ai/details/publication/pub.1043009411"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-08-04T17:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/chapter/chapter_144.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-0-85729-402-9_28"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-0-85729-402-9_28'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-0-85729-402-9_28'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-0-85729-402-9_28'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-0-85729-402-9_28'


 

This table displays all metadata directly associated to this object as RDF triples.

118 TRIPLES      21 PREDICATES      93 URIs      86 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-0-85729-402-9_28 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ne4e9c501c5a7499a94a6c1de500d7e55
4 schema:datePublished 2004
5 schema:datePublishedReg 2004-01-01
6 schema:description Instead of relying mainly on personal experience with new diagnostic and treatment methods, a wise physician depends on studies reported in the medical literature.Proof of efficacy of new agents is currently provided by double-blind, randomized, placebo-controlled trials (RCTs), generally involving more than one medical center.Relative risk values alone give incomplete information. It is necessary to know also the basal risk of the outcome in question and to assess its importance, both medically and personally.Cost/benefit analyses have become increasingly important in the development of practice guidelines, in the registration of drugs, and in the deployment of screening tests and preventive regimens.The results of treatment trials of bone active agents must be analyzed in a way that is consistent with the underlying biology.A physician tries a new bone active agent in his practice. His patients seem to improve and he is enthusiastic. Another physician, trying the same agent, sees little patient improvement but notes serious side effects and becomes convinced that the drug is more trouble than it is worth. Both are wrong, as the Hippocratic maxim suggests. It is impossible to say in individual cases how much of the difference between the two experiences is due to placebo effects, to variations in the biologic makeup of the patients concerned, or simply to random chance.
7 schema:genre chapter
8 schema:isAccessibleForFree false
9 schema:isPartOf N6ff302fd54f5404c97ed8b6bf9a32ea4
10 schema:keywords Hippocratic maxim
11 Medical Center
12 active agents
13 agents
14 analysis
15 basal risk
16 benefit analysis
17 biology
18 bone active agents
19 cases
20 center
21 chance
22 cost/benefit analysis
23 data
24 deployment
25 development
26 differences
27 drugs
28 effect
29 efficacy
30 experience
31 guidelines
32 importance
33 improvement
34 incomplete information
35 individual cases
36 information
37 literature
38 makeup
39 maxim
40 medical literature
41 method
42 more trouble
43 new agents
44 new data
45 outcomes
46 patient improvement
47 patients
48 personal experience
49 physicians
50 placebo effect
51 placebo-controlled trial
52 practice
53 practice guidelines
54 preventive regimens
55 proof
56 proof of efficacy
57 questions
58 random chance
59 regimens
60 registration
61 registration of drugs
62 relative risk values
63 results
64 risk
65 risk values
66 same agents
67 serious side effects
68 side effects
69 study
70 test
71 treatment methods
72 treatment trials
73 trials
74 trouble
75 values
76 variation
77 way
78 wise physician
79 schema:name How to Interpret New Data
80 schema:pagination 213-217
81 schema:productId N1601bd0566c04b2193e30c5a338bc2bb
82 Nab38426e83934db49f038d7f662fd274
83 schema:publisher Nd8d1352b245542ccbe08cdd48e75545d
84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043009411
85 https://doi.org/10.1007/978-0-85729-402-9_28
86 schema:sdDatePublished 2022-08-04T17:14
87 schema:sdLicense https://scigraph.springernature.com/explorer/license/
88 schema:sdPublisher Nadbeb4177637460d9fce00ded069ed01
89 schema:url https://doi.org/10.1007/978-0-85729-402-9_28
90 sgo:license sg:explorer/license/
91 sgo:sdDataset chapters
92 rdf:type schema:Chapter
93 N1601bd0566c04b2193e30c5a338bc2bb schema:name dimensions_id
94 schema:value pub.1043009411
95 rdf:type schema:PropertyValue
96 N6ff302fd54f5404c97ed8b6bf9a32ea4 schema:isbn 978-0-85729-402-9
97 978-1-85233-757-5
98 schema:name Osteoporosis in Clinical Practice
99 rdf:type schema:Book
100 Nab38426e83934db49f038d7f662fd274 schema:name doi
101 schema:value 10.1007/978-0-85729-402-9_28
102 rdf:type schema:PropertyValue
103 Nadbeb4177637460d9fce00ded069ed01 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 Nd8d1352b245542ccbe08cdd48e75545d schema:name Springer Nature
106 rdf:type schema:Organisation
107 Ne4e9c501c5a7499a94a6c1de500d7e55 rdf:first sg:person.0645437522.96
108 rdf:rest rdf:nil
109 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
110 schema:name Medical and Health Sciences
111 rdf:type schema:DefinedTerm
112 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
113 schema:name Clinical Sciences
114 rdf:type schema:DefinedTerm
115 sg:person.0645437522.96 schema:familyName Heaney
116 schema:givenName Robert P.
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645437522.96
118 rdf:type schema:Person
 




Preview window. Press ESC to close (or click here)


...